Detalles de la búsqueda
1.
Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults.
Br J Clin Pharmacol
; 90(1): 274-285, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37621050
2.
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
N Engl J Med
; 382(13): 1232-1243, 2020 03 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-32212519
3.
Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants.
Br J Clin Pharmacol
; 89(7): 2236-2245, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36822839
4.
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254.
Clin Infect Dis
; 75(5): 786-794, 2022 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34996113
5.
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Antimicrob Agents Chemother
; 66(6): e0175121, 2022 06 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35502922
6.
Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women.
Br J Clin Pharmacol
; 88(4): 1704-1712, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34427938
7.
A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33753329
8.
Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
J Antimicrob Chemother
; 76(11): 2958-2964, 2021 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34297843
9.
Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay.
J Antimicrob Chemother
; 76(3): 648-652, 2021 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33241285
10.
Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
Br J Clin Pharmacol
; 87(9): 3501-3507, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33533507
11.
Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
PLoS Pathog
; 12(11): e1005990, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27893830
12.
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).
Clin Infect Dis
; 65(3): 442-452, 2017 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28369211
13.
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Antimicrob Agents Chemother
; 60(5): 2782-9, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26902761
14.
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
J Antimicrob Chemother
; 69(3): 573-81, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24128669
15.
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Antimicrob Agents Chemother
; 57(9): 4172-80, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23774428
16.
In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.
Antimicrob Agents Chemother
; 57(11): 5500-8, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23979732
17.
Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants.
Pharmacol Res Perspect
; 11(6): e01151, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37961928
18.
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Infect Dis Ther
; 12(9): 2321-2335, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37751019
19.
In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068.
Antimicrob Agents Chemother
; 56(7): 3498-507, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22547625
20.
A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
HIV Clin Trials
; 13(3): 119-30, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22592092